Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

High altitude illness can be prevented by a simple rule: don't go too high, too fast. Drugs can also be used, and Dr Basnyat showed that a much lower dose of Diamox, a commonly used drug, is as effective. His research also focusses on the effect of high altitude on pilgrims, an older, poorer and more vulnerable population.

Q: What is altitude illness?

Buddha Basnyat: Altitude illness is like a hangover that starts at about 2,500 metres or 10,000 feet. It is a headache and nausea. These are the first signs of acute mountain sickness and they can be life threatening. They can go on to cause cerebral oedema and pulmonary oedema, which is water in the lungs and water in the head. It can be life threatening.

Q: How can you minimise your chances of suffering from altitude illness?

BB: By making sure you are aware of this disease entity, and once you are aware you will not go up too high too fast. The suggestion is that after 10,000 feet or 3,000 metres, the present night's altitude should not be more than 400 or 500 metres more than the previous night. You should not increase by more than 400 or 500 metres so that your body has time to acclimatise. Going up slowly, in other words. Taking your time and not going up too high too fast. That is the main issue here.

Q: How can we increase awareness of altitude illness?

BB: There is not enough awareness about this. For instance, very recently in Mount Kilimanjaro which is a standalone mountain in Kenya, there was a tragedy. A racing car driver, Mr Zulu from South Africa, went on a five-day trip to Kilimanjaro, going up too high too fast, and he died. It was very tragic. However, from the tragedy, I hope that people will learn that they should go up slowly, this is important. In the Himalayas there is much more awareness about altitude illness and I think the focus now needs to be on this mountain Kilimanjaro which is politically incorrect but I think it is Killer Kili. Awareness needs to be generated and maybe taking advantage of this tragedy but to good effect to help other people.

Q: What are the most important lines of research which have developed over the last 5-10years?

BB: Probably the most important line of research that has developed is in the field of genetics. Professor Sir Peter Ratcliffe from the Nuffield Department of Medicine is involved, through the discovery of a protein called HIF, hypoxia-inducible factor protein. If you have an over-representation of this protein, you are better able to adapt to high altitude. This is why Tibetans it seems have an over-representation of this protein and they are able to adapt better. This HIF protein, this factor, is important. It seems it is a master switch that impacts on cardiovascular problems, cancer problems. It is a bigger deal than high altitude hypoxia.

Q: Why does your research matter and why should we fund it?

BB: People live at high altitude and travel to high altitude. Populations in South American Altiplano, in the Tibetan plateau, there are thousands and thousands of people that live there. We have restricted our discussion so far to acute mountain sickness, but there is something called chronic mountain sickness which people living at high altitude can suffer from. It is an important area and people travel up to high altitude, millions go up to high altitude. Obviously there is a lot of human movement so it is very important area which does not get enough emphasis.

Q: How does your research fit in to translation medicine within the department?

BB: In terms of translational medicine, we have studied a drug which prevents altitude sickness. It is very well known and is called Diamox. A big dose of Diamox was suggested prior to our studies: they suggested 750mg. There was big study that came out in the BMJ (British Medical Journal) around 2000. We said we did not think this was right, we have anecdotal evidence of a most lower doses working. We clearly showed that a lower dose causes less side effects, 250mg maybe even less is what our data was showing. Rather than giving this huge, hefty dose of 750mg for the prevention of acute mountain sickness, you can get by with a lowly 250mg. That is one area where we have been helpful.

We have started focusing on another very important area. You think of thousands of tourists going up to high altitude, but millions of pilgrims with what is called co-morbidities, diabetes or others, and they are not your trekkers and climbers but are people who want to go to the sacred sites that are at very high altitudes. For example there is a sacred lake in South Asia, there are many lakes like this and pilgrims go up. They make a pilgrimage. Millions of them go up as opposed to thousands of tourists. We need to focus on keeping the tourists safe, but we also need to keep the pilgrims safe. They are older, poorer and more vulnerable. We are focusing attention on this.

Buddha Basnyat

OUCRU-Nepal

The mission of OUCRU-Nepal, set up in 2003 in Kathmandu, is to train young Nepalese clinician scientists, and help build Nepal's scientific and clinical future.

Director of OUCRU-Nepal, Dr Buddha Basnyat studies high altitude illness as well as undifferentiated febrile illness in the tropics, both common but neglected problems in Nepal.

More podcasts related to Global Health

Mike English: Health services that deliver for newborns

Basic hospital care may be key to saving newborn lives. Professor Mike English outlines a multidisciplinary project engaging policy-makers and practitioners in Kenya. This project demonstrated poor coverage of Nairobi’s 4.25 million population if a sick newborn baby needs quality hospital care. Using novel research approaches the team also identified how severe shortages of nurses contribute to poor quality of care for patients and negatively affect nurses themselves.

Tran Hien: Infectious diseases in the tropics

Although incidence of malaria has decreased in Vietnam, the burden of infectious diseases remains high and weighs heavily on the health care system. Clinical research aims to allow investments to go further: findings in the laboratory, tested in clinical trials and then applied to the community, help improve diagnosis and management.

Ronald Geskus: Sophisticated biostatistics for complex clinical research

The role of biostatisticians in clinical research is to contribute to trial design, by calculating sample size for example, and to help draw correct conclusions from the data, discriminating important information from noise. They are instrumental in the translation of a practical problem into a statistical model, and the translation of the result into practice.

Rogier Van Doorn: Research at OUCRU Hanoi

Antibiotics are widely used in Vietnam, leading to widespread antimicrobial resistance. Monitoring antibiotic use helps inform the government to change treatment guidelines and implement antibiotic stewardship programmes. This may also prevent the transmission of resistant bacteria outside the country.

Heiman Wertheim: Clinical research in low and middle-income countries

Drug resistant infections are a global crisis and we cannot focus on our own country only. Clinical trials in low and middle income countries where the burden is highest, as well as work with local communities and engagement with policy makers help influence public health policies.

Guy Thwaites: Tuberculosis meningitis

Tuberculosis meningitis affects a fractions of TB patients but causes high levels of mortality and morbidity. A recent trial at OUCRU showed that aspirin can greatly improve outcomes. Such trial is typical of the work done in our Vietnam units, where all the research is focussed on improving the outcome for patients directly.

Motiur Rahman: OUCRU laboratory management

OUCRU laboratories provide support to the unit’s extensive clinical research programme, from level 2 laboratory to SAPO 4 laboratory for high-risk pathogens responsible for zoonotic infections. Early diagnosis and detection of antimicrobial resistance helps prescribe the right medicine in time, contributing to better patient management.

Raph Hamers: Developing collaborative clinical trials in Indonesia

Indonesia is a very populous country with a huge burden of infectious diseases such as TB, malaria, HIV and CNS infections. Running clinical trials requires high levels of expertise, currently developed and strengthened by institutions such as IOCRL (Universities of Indonesia and Oxford Clinical Research laboratory). Better collaborations will also help great ideas make a bigger impact.

Jeremy Day: Central nervous system and HIV infections in Vietnam

Brain infections such as meningitis and encephalitis are highly debilitating diseases, and an accurate diagnostic is essential to give patients the best treatment available. For cryptococcal meningitis, clinical trials focus on prevention, for an early diagnosis, and novel ways to use existing treatments or repurpose old drugs.

Abhilasha Karkey: Connecting research with communities in Nepal

Antimicrobial resistance is a huge burden in Nepal, particularly in hospitals where many nosocomial infections are caused by resistant pathogens. With limited resources, little infection controls and proper guidelines in place, finding out the main risk factors helps reduce infection rates within a hospital and better target vaccination campaigns.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.